| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
23001 |
| Drug |
Difelikefalin |
| Brand |
Kapruvia® |
| Indication |
For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. |
| Rapid review commissioned |
09/01/2023 |
| Rapid review completed |
02/02/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of difelikefalin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/03/2023 |
| Pre-submission consultation with Applicant |
16/05/2023 |
| Full submission received from Applicant |
12/09/2023 |
